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Finnish epilepsy patients who have maternal
relatives with epilepsy, sensorineural hearing
impairment or diabetes mellitus
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Background: Mitochondrial diseases caused by mutations in mitochondrial DNA (mtDNA) affect tissues with high
energy demand. Epilepsy is one of the manifestations of mitochondrial dysfunction when the brain is affected. We
have studied here 79 Finnish patients with epilepsy and who have maternal first- or second-degree relatives with
epilepsy, sensorineural hearing impairment or diabetes mellitus.
Methods: The entire mtDNA was studied by using conformation sensitive gel electrophoresis and PCR fragments
that differed in mobility were directly sequenced.
Results: We found a common nonsynonymous variant m.15218A > G (p.T158A, MTCYB) that occurs in haplogroup
U5a1 to be more frequent in patients with epilepsy. The m.15218A > G variant was present in five patients with
epilepsy and in four out of 403 population controls (p = 0.0077). This variant was present in two branches in the
phylogenetic network constructed on the basis of mtDNA variation among the patients. Three algorithms predicted
that m.15218A > G is damaging in effect.
Conclusions: We suggest that the m.15218A > G variant is mildly deleterious and that mtDNA involvement should
be considered in patients with epilepsy and who have a maternal history of epilepsy, sensorineural hearing
impairment or diabetes mellitus.
Keywords: Epilepsy, mtDNA, Mitochondrial DNA, Mitochondrial haplogroups, Sequence variation, Nonsynonymous
mutation, Maternal inheritance, Haplogroup U5a1Background
Epilepsies are a heterogeneous group of complex seizure
disorders, which can be classified according to under-
lying pathology or clinical manifestation. Main classes of
epilepsy in adults are localization related (focal, partial),
generalized, undetermined and epilepsies associated with
special syndromes. Causes for epilepsy include structural
damage of brain tissue such as trauma, stroke and tu-
mours, central nervous system infections and genetic* Correspondence: kari.majamaa@oulu.fi
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reproduction in any medium, provided the orcauses [1,2]. Some epilepsy cases remain etiologically
undetermined.
Epilepsy is a frequent manifestation of mitochondrial
disorders, as the brain is often severely affected in these
diseases [3]. Seizures are commonly seen in Alpers-
Huttenlocher syndrome, Leigh syndrome, MELAS syn-
drome (mitochondrial encephalomyopathy, lactic acidosis
and stroke-like episodes), MEMSA syndrome (myoclonic
epilepsy, myopathy, sensory ataxia) and in ataxia neur-
opathy spectrum [4,5]. The most common mitochondrial
DNA (mtDNA) mutation causing epilepsy is m.8344A >G
in the MTTK gene. It causes MERRF syndrome (myoclo-
nus epilepsy associated with ragged red fibers) [6]. Muta-
tions in the MTTF gene have also been reported to cause
severe epilepsy [7]. Pathogenic mtDNA mutations ared. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the wild type variant are present in the mitochondria. The
proportion of the mutant variant must exceed a certain
threshold before symptoms of mitochondrial disease be-
come manifest [8]. Other mitochondrial diseases which
can present with seizure symptoms are neuropathy, ataxia,
retinitis pigmentosa syndrome and Kearns-Sayre syn-
drome [4]. Furthermore, mitochondrial oxidative stress
may play a role in epileptogenesis by virtue of affecting
neuronal excitability [9].
It has been suggested that mildly deleterious mtDNA
variants are involved in the pathogenesis of many degen-
erative diseases [10-12]. Such variants are present in the
population without being subjected to selection [13], but
are maintained more by genetic drift [14]. The increased
risk for diseases with mitochondrial contribution in patho-
genesis is most likely determined by a balance between
beneficial and damaging mtDNA mutations within
haplogroups. In the case of some haplogroups, the balance
leans more towards the deleterious side. Also, deleterious
mtDNA mutations have been suggested to be population
specific so that a given variant may be associated with a
disease in one population, but not in the other [14].
Deleterious mtDNA mutations are the cause of the
MELAS syndrome [15] and the MERRF syndrome [16]. In
addition to the full-blown encephalomyopathic MELAS
syndrome, patients with the m.3243A >G mutation often
present with diabetes mellitus or sensorineural hearing
impairment (SNHI) [17]. These two phenotypes as well as
epilepsy are common in the population and, therefore, pa-
tients with these diseases are good subjects in the search
of mildly deleterious mtDNA variants. In order to assess
the role of such variants and mtDNA haplogroups we de-
termined the entire mtDNA sequence of 79 Finnish pa-
tients with epilepsy and with a maternal history of
epilepsy, diabetes mellitus or SNHI. The pathogenic po-
tential of all nonsynonymous mutations was also analysed.
Methods
Subjects and samples
Most adult patients with epilepsy in the province of
Northern Ostrobothnia make regular visits to the out-
patient Neurology Department of the Oulu University
Hospital. During a one year period, a physician involved in
the study reviewed the charts of the visiting patients and
once the diagnosis of epilepsy was confirmed, the patient
was requested to fill out a family history questionnaire.
We did not make distinctions between the etiologies or
types of epilepsy. We identified 223 patients with epilepsy
that had any combination of epilepsy, sensorineural hear-
ing impairment or diabetes mellitus in their first- or
second-degree maternal relatives. Blood samples were
obtained from 165 patients and then 79 patients were se-
lected if the number of maternal relatives with epilepsy,diabetes or sensorineural hearing impairment was ≥ 2 (38
patients) or if a family history score was ≥ 0.1 in families
with one maternal relative with epilepsy or sensorineural
hearing impairment (41 patients). The family history score
was calculated using the formula Naffected/Ntotal [18].
Patients were tested not to harbour m.3243A >G or
m.8344A >G mutation using restriction fragment analysis
prior to selecting samples for this study.
Samples from healthy blood donors (N = 403) obtained at
local Finnish Red Cross offices served as population con-
trols [19]. It was required that the donors did not report
neurological ailments, diabetes and sensorineural hearing
impairment of their own or of their mothers. It was also re-
quired that the donor and the mother had been born in the
same province. All the patients signed an informed consent
to participate in the study. The Ethics Committee of the
Medical Faculty, University of Oulu, and that of Finnish
Red Cross have approved the study protocol.
Conformation Sensitive Gel Electrophoresis (CSGE)
Total DNA was extracted from blood using the QIAmp
Blood Kit (Qiagen, Valencia, CA, U.S.A.). Mitochondrial
DNA haplogroups were determined by restriction frag-
ment analysis [20]. CSGE was performed as described
earlier [21,22]. MtDNA coding region (nucleotides m.577-
16090) was amplified in 63 partially overlapping fragments
covering the entire mtDNA coding region. The primers
were ~22 bp in length and they were designed as previously
reported [21]. The mean PCR fragment size was 350 bp
and each amplified fragment overlapped by about 80 nucle-
otides with its neighbouring fragments [see Additional file
1]. PCR fragments were amplified in a total volume of 30 μl
in 30 cycles: denaturation at 94˚C for 1 min, annealing at a
primer-specific temperature and extension at 72˚C for
1 min and a final extension for 10 min. Touchdown-PCR
protocol was used in parallel and yielded similar results. 3-
10 μl of the PCR product was used for heteroduplex forma-
tion. Each amplified fragment was mixed with a reference
sample and denatured at 95˚C for 5 min and annealed at
68˚C for 30 min for heteroduplex formation. Samples were
electrophoresed on 15% polyacrylamide gel overnight at a
constant voltage of 400 V at room temperature. The gel
was stained in 150 μg/l of ethidium bromide for 5 min and
destained in water after which it was transferred to UV
transluminator and photographed (Grab-IT Annotating
Grabber 2.04.7; UVP Inc. Upland, CA, U.S.A.). Previous
data have suggested that the limit of detection of
heteroplasmy in various heteroduplex screening assays
is < 10% [23].
Sequencing
PCR fragments that differed in mobility in CSGE were
purified with exonuclease I and shrimp alkaline phos-
phatase [24] and sequenced (ABI PRISM™ 377 and ABI
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ator Cycle Sequencing Kit; Amersham Pharmacia Biotech
Inc. Piscataway, NJ, U.S.A.). Same primers were used for
sequencing and amplification of the 63 PCR fragments.
CSGE has previously been shown to be a sensitive (98.8%)
and specific (100%) method for detecting mtDNA variants
[25]. The D-loop (nucleotides m.15975 – 725) was ampli-
fied in a unique PCR fragment and directly sequenced.
Analysis of substitutions
Sequences were compared to the revised Cambridge refer-
ence sequence NC_012920 [26] and to mtDNA sequences
available in the GiiB-JST mtSNP database [http://mtsnp.
tmig.or.jp/mtsnp/index_e.shtml] [27], mtDB Human Mito-
chondrial Genome database [http://www.mtdb.igp.uu.se]
[28], HmtDB database [http://www.hmtdb.uniba.it] [29]
and Mitomap [http://www.mitomap.org] [30] accessed in
June 2012. Nonsynonymous polymorphisms were consid-
ered rare if a total of three or less sequences had been
reported in the above mentioned databases. Sequences
were also compared to complete mtDNA sequences of 192
population controls obtained from the same area as the
patients [19,31].
Novel substitutions were confirmed by restriction frag-
ment analysis and/or sequencing in both directions at least
twice from separate PCR products. Variant was regarded
as a previously reported pathogenic mutation if it was
listed as such in the Mitomap. Base conservation was de-
termined using the GiiB-JST mtSAP evaluation http://
mtsnp.tmig.or.jp/cgi-bin/mtsnp/specAlign/ctrlSpecAlignE.
cgi for nonsynonymous variants [27] and Mamit-tRNA for
tRNA variants http://mamit-trna.u-strasbg.fr/ [32]. Phylo-
genetic networks based on mtDNA sequence variation in
the coding region and the D-loop were constructed using
the median algorithm [33].
Analysis of pathogenic potential of nonsynonymous
mtDNA variants
The pathogenic potential of nonsynonymous mtDNA
variants detected in epilepsy patients was analyzed with
PolyPhen-2, version 2.2.2 [http://genetics.bwh.harvard.
edu/pph2/] [34], SIFT BLink [http://sift.jcvi.org/www/
SIFT_BLink_submit.html] [35] and PMut [http://mmb.
pcb.ub.es] [36]. PolyPhen-2 uses a Bayesian algorithm to
calculate the pathogenic potential of a nonsynonymous
mutation using both evolutionary conservation data
and the structural similarities/differences of amino
acids. The mutations are classified as benign (< 50%
chance of pathogenic effect), possibly deleterious
(> 50% chance of pathogenic effect) and probably dele-
terious (> 90% chance of pathogenic effect). SIFT BLink
uses evolutionary conservation data to assess whether a
nonsynonymous variant is pathogenic. It predicts a
variant to be either functionally important (0 being themost pathogenic) or unimportant (1 being the most
benign). PMut is based on evolutionary information de-
rived from multiple sequence alignments. Variants are
classified as pathogenic or benign and a reliability score
is given (0, lowest reliable; 9, very reliable).
Results
Nonsynonymous variants predicted to be damaging
CSGE and sequencing were used to determine complete
mtDNA sequences of 79 patients with epilepsy. MtDNA
sequences were then used to construct a phylogenetic net-
work separately for the coding region (Figure 1) and the
D-loop (Figure 2). Exact test of population differentiation
[38] revealed no differences in the frequencies of mtDNA
haplogroups between patients and controls (Table 1).
We found 52 different nonsynonymous mtDNA variants
in the 79 patients. Evaluation of the pathogenic potential
of all the nonsynonymous variants was then carried out by
using PolyPhen-2, SIFT BLink and PMut. PolyPhen-2 pre-
dicted the lowest and SIFT BLink the highest number of
pathogenic mutations (Figure 3). All three algorithms con-
cordantly predicted five nonsynonymous variants to be
damaging (Table 2). One of these variants was m.15218A
>G (p.T158A, MTCYB), which was present in two
mtDNA haplotypes in five patients (Figure 4). Four out of
403 population controls belonged to the major haplotype
while none belonged to the minor haplotype (p = 0.0077
for difference between cases and controls, Fisher’s exact
two-tailed test). The presence of m.15218A >G in the five
patients and four controls and the absence of the variant
in samples 40 and 48 was confirmed by sequencing the
fragment amplified in two separate reactions in both L-
and H-directions. Patients 37 and 75 with m.15218A >G
had identical mtDNA sequences, but family information
did not suggest immediate relatedness. The clinical fea-
tures of the five patients were variable (Table 3). Another
variant predicted to be damaging was m.9903T > C
(p.F233L, MTCO3) that occurred in two patients but
not in the controls (p = 0.08, Fisher’s exact two-tailed
test). The remaining three variants did not differ in fre-
quency between patients and controls.
Nonsynonymous variants with previously reported
disease associations
We observed five nonsynonymous mtDNA variants with
previously reported disease associations. Three of them
were situated in the MTCO1 gene. The m.6489C >A
transversion (p.L196I, MTCO1) has been reported in
a patient with therapy-resistant epilepsy [41] and in
patients with matrilineal diabetes [42]. The second
variant m.6253T > C (p.M117T, MTCO1) has been
reported with an association to prostate cancer [43] and
the third variant m.7444G >A (p.*514K, MTCO1) in
association with Leber’s hereditary optic neuropathy or
Figure 1 Phylogenetic network based on mtDNA coding region sequences in 79 patients with epilepsy and with a maternal history of
epilepsy, SNHI or diabetes mellitus. Nodes represent patients. Inside the nodes, patients are identified by numbers 1-79. Outgroup is an
African sequence [GenBank: AF346980]; CRS is the revised Cambridge Reference Sequence [GenBank: NC_012920]. Unless marked otherwise,
mtDNA variants are transitions. Superscripts indicate transversions and novel mutations. @ = back mutation, * = heteroplasmic mutation, followed
by patient number in parenthesis if required. D9bp = deletion spanning the positions m.8281 and m.8289. Nonsynonymous variants are in red
font, underlined red variants were concordantly predicted to be pathogenic by PolyPhen-2, PMut and SIFT BLink analyses.
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Figure 2 Phylogenetic network based on mtDNA D-loop sequences in 79 patients with epilepsy. Nodes represent patients. Inside the
nodes, patients are identified by numbers 1-79. Outgroup is an African sequence [GenBank: AF346980]; CRS is the revised Cambridge Reference
Sequence [GenBank: NC_012920]. Unless marked otherwise, mtDNA variants are transitions. Superscripts indicate transversions and novel
mutations. @ = back mutation, * = heteroplasmic mutation.
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Table 1 Frequencies of mtDNA haplogroups in 79 Finnish
patients with epilepsy and in 403 controls
Patients Controls1
Haplogroup (N) (%) (N) (%)
H 32 25.3 162 40.1
U 21 16.6 112 27.8
V 7 5.5 22 5.4
W 5 3.9 37 9.2
J 4 3.2 18 4.4
K 3 2.4 12 2.9
T 3 2.4 10 2.5
I 2 1.6 14 3.5
X 2 1.6 4 0.9
M 0 0 10 2.5
Other 0 0 1 0.2
1Meinilä et al. 2001 [19].
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cated in MTND5 including m.12811T > C (p.Y159H) and
m.13637A >G (p.Q434R). These variants have been postu-
lated to affect the phenotype of Leber’s hereditary optic
neuropathy [47-49]. Prediction algorithms did not support
a pathogenic role for these variants.Rare mtDNA variants
Four nonsynonymous polymorphisms found in the pa-
tients were considered rare (Table 4). Three of them have
been previously reported in Finnish individuals. Two of
the rare nonsynonymous mutations, m.8923A >G and
m.15725C > T, were predicted to be damaging with SIFT
BLink and PMut, but not with PolyPhen-2. In addition, a
novel m.11392A >G synonymous change in MTND4 was
also discovered in a sample belonging to haplogroup K.Figure 3 Number of nonsynonymous variants predicted to be pathog
predictions were carried out on 52 nonsynonymous mtDNA mutations in 7
analyses. Gray bar, number of variants predicted to be benign; black bar, nDiscussion
The m.15218A >G (p.T158A, MTCYB) variant was found
in five patients with epilepsy and with a maternal history
of epilepsy, SNHI or diabetes. The patients belonged to
haplogroup U5a. Haplogroup U5 has previously been sug-
gested to have possible disease associations, as it has been
found to be more frequent in patients with occipital stroke
and migrainous stroke [50]. Stroke-like episodes in mito-
chondrial diseases can resemble occipital epileptic seizures
[51] and mitochondrial diseases often manifest themselves
only in epileptic seizures [5]. Haplogroup U5a has been as-
sociated with a rapid progression to AIDS and death among
HIV-1 infected patients, especially those harbouring the
m.15218A >G variant [52].
Haplogroup U5 is more common in Finland than the rest
of Europe. Its frequency is ~ 30% in the Finnish population
compared to 18 - 22% in Western and Eastern Europe [30].
Haplogroup U5 is especially common in Northern Finland
and its variation is low there. The reason for this is
suspected to be a founder effect of a relatively small settler
group that colonized northern Finland after the 16th cen-
tury [21]. Furthermore, haplogroup U constitutes 32-52%
of mtDNA in the indigenous Saami people of Northern
Scandinavia and Northwestern Russia. Admixture of Finns
and the Saami has been reported in the North of Finland
[19,53]. In order to avoid bias caused by geographical differ-
ences in haplogroup frequencies we collected our patient
and control samples from the same area.
We used three different methods for predicting
the pathogenic potential of nonsynonymous mutations.
PolyPhen-2 predicted the highest number of benign
polymorphisms, whilst SIFT BLink predicted the highest
number of pathogenic mutations. PolyPhen-2 has been
reported to be sensitive in predicting neutral polymor-
phisms [54] with a 5% false negative rate for benignenic or benign in 79 patients with epilepsy. Pathogenicity
9 patients with epilepsy by using PolyPhen-2, SIFT BLink and PMut
umber of variants predicted to be pathogenic.
Table 2 Nonsynonymous mtDNA variants predicted to be deleterious in 79 patients with epilepsy













m.9055G > A MTATP6 p.A177T 84.5 0.01 Pathogenic 7 446 Various
m.9903T > C MTCO3 p.F233L 75.6 0 Pathogenic 7 4 Africa, Finland, Italy6
m.12613G > A MTND5 p.A93T 97.2 0 Pathogenic 2 5 Finland, Russia/Tatar
m.14198G > A MTND6 p.T159M 99.9 0 Pathogenic 0 5 Finland, Japan, Israel, Spain7
m.15218A > G MTCYB p.T158A 89.3 0.04 Pathogenic 2 164 Various
1 http://genetics.bwh.harvard.edu/pph2/ PolyPhen-2 pathogenicity prediction levels: Possibly damaging > 50%, probably damaging > 90%.
2 http://sift.jcvi.org/www/SIFT_BLink_submit.html SIFT BLink pathogenicity prediction levels: Damaging amino acid substitutions ≤ 0.05.
3 http://mmb.pcb.ub.es.
4 PMut pathogenicity prediction reliability score, 0 (lowest reliable) to 9 (most reliable).
5 Number of sequences among 2704 sequences in mtDB database http://www.mtdb.igp.uu.se/ and among 8813 sequences in HmtDB database http://www.
hmtdb.uniba.it accessed in February 2013, each sequence hit was counted only once if present in both databases.
6 Patient with breast cancer [38].
7 Patient with glioma [39].
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reported to be more reliable in detecting truly pathogenic
variants. Both PMut and SIFT BLink make use of evolu-
tionary conservation data and yield comparable results,
while PolyPhen-2 makes use of physical and chemical
properties of amino acids in addition to evolutionary con-
servation data. We considered the variants that all three
algorithms predicted pathogenic to be the best candidates
for pathogenic mutations.Figure 4 Schematic presentation of haplotypes in mtDNA haplogroup
population controls (N = 19); grey nodes, sequences found in HmtDB datab
population controls by numbers C1 - C21 [19], database controls by numb
shown. CRS, the revised Cambridge Reference Sequence [GenBank: NC_012
accession for database controls; D1 - D3: AY339528, AY339529, EF657601; D
GU459066, HM852873, DQ489510, GQ160809, GU296652, GU296636, GU296
EU523128, DQ904330, DQ826448, EF657412; D25 - D29: AY339523, DQ1128
AY339526, AY339527, EF657616, EF363686, EF177408, EU215455, GU391321
GU296650, GU296635, GU296634, GU296626, GU296615, GU296613, GU296
GU296548, GU797137, EU007851, EU124886, AM260578, AM260577, AM260The m.15218A >G mutation in MTCYB was predicted
to be pathogenic by the three algorithms. This mutation
leads to substitution of a conserved hydrophilic threonine
by a hydrophobic alanine at position 159 of the cyto-
chrome b subunit of complex III. Out of the 60 species
compared, 53 species harbour threonine in this position
[27] and only Barbary macaque (Macaca sylvanus) har-
bours alanine in this position of the subunit. The cyto-
chrome b subunit of complex III forms the catalytic coreU5a1. Red nodes, patients with epilepsy (N = 9); white nodes, Finnish
ase (N = 66). Inside the nodes, patients identified by numbers;
ers D1 – D66. Only discriminant variants for the four haplotypes are
920]. Unless marked otherwise, variants are transitions. GenBank
4 – D24: GU296581, GU296583, GU296594, GU296558, HM852852,
601, GU296595, EU597527, EU698951, GQ368895, GU206811,
38, EF397754, HM490393, JN604831; D30 - D66: AY339524, AY339525,
, GQ214520, HM246245, HM229344, GU122993, HM144108, HM142902,
605, GU296602, GU296597, GU296596, GU296580, GU296574,
576, AM260573, AM260572, HM765474.
Table 3 Clinical features of patients with epilepsy and with m.15218A > G
Patient ID Sex Age at onset Seizure classification Etiology Family history
37 F 7 Generalized tonic-clonic seizures Unknown Sister with epilepsy
75 F 47 Focal with impairment of consciousness, involving subjective
sensory phenomena, evolving to a bilateral, convulsive seizure
Unknown Sister with epilepsy
43 F 0.5 Focal with impairment of consciousness, with observable motor or
autonomic components, occasionally evolving to a bilateral,
convulsive seizure
Unknown Mother, brother with epilepsy
52 F 62 Focal with impairment of consciousness and with observable
motor components
Structural Brother, sister with DM, sister with HI
53 M 25 Focal with impairment of consciousness, involving subjective
sensory phenomena
Unknown Mother with HI
DM diabetes mellitus, HI hearing impairment. Seizure classification and assessment of etiology conform to the criteria in the Report of the ILAE Commission on
Classification and Terminology [40].
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Rieske iron-sulphur protein. Changes in this subunit have
been shown to cause changes to the catalytic function of
complex III, thus leading to complex III defects [55].
The m.15218A >G variant is present in haplogroups
M7, M10, HV, H13 and U5a1 [56] indicating that
m.15218A >G is a homoplasic variant. We found this vari-
ant in two haplotypes within haplogroup U5a1, the major
haplotype being identical to that detected previously in
Finnish population controls [31] and the minor haplotype
being identical to that in a Finnish patient with diabetes
mellitus [42]. Evolutionary conservation of the amino acid
position, results from the prediction algorithms and the
homoplasic nature of the variant suggest that m.15218A >
G is mildly deleterious rather than a neutral variant.
The m.14198G > A variant (p.T159M, MTND6) found
in one patient was also predicted to be damaging. This
variant has been found to exist in haplogroups G and H
[28,29], although in our patient data it was present in
haplogroup U5a1. PMut predicted it to be pathogenic
but the reliability score was low and, therefore, we can-
not make conclusions of its true pathogenic potential. It
is noteworthy though that it was also found in
haplogroup U5a1.Table 4 Rare mtDNA variants discovered in 79 patients with e








8923A > G MTATP6 p.T133A 1.1 0 Pathogen
9480T > C MTCO3 p.F92L 38.7 0.51 Pathogen
14564A > G MTND6 p.V37A 0 1 Neutral
15725C > T MTCYB p.L327F 0.1 0.03 Pathogen
11392A > GNovel MTND4 syn n.a. n.a. n.a.
syn synonymous variant, n.a. not applicable.
1 http://genetics.bwh.harvard.edu/pph2/ PolyPhen-2 pathogenicity prediction levels
2 http://sift.jcvi.org/www/SIFT_BLink_submit.html SIFT BLink pathogenicity predictio
3 http://mmb.pcb.ub.es.
4 PMut pathogenicity prediction reliability score, 0 (lowest reliable) to 9 (most reliab
5 Number of hits among 2704 sequences in mtDB database http://www.mtdb.igp.u
accessed in February 2013. Each sequence hit was counted once, if present in both
6 A patient with Leber’s hereditary optic neuropathy [49].
GenBank accession: KC763372 - KC763450.Other mutations predicted to be pathogenic by the
three algorithms were m.9903T > C (p.F233L, MTCO3)
and m.9055G > A (p.A177T, MTATP6). The m.9033T >
C variant occurred in two patients belonging to hap-
logroup K but was not present in the controls. It is present
in one haplogroup L2a sequence [GenBank: EF657335], in
two haplogroup K1c1 sequences [GenBank: EU262720,
GenBank: EU753433] and in a haplogroup X2 sequence
[39] in the HmtDB and mtDB databases [28,29]. We sug-
gest that m.9033T > C is a rare homoplasic variant occur-
ring in haplogroups K, X and L and that its pathogenic
nature is uncertain. The five nonsynonymous mutations
with previous disease association were not predicted to
be deleterious but, interestingly, m.6489C >A (p.L196I,
MTCO1) has been reported to be associated with therapy-
resistant epilepsy [41].
The m.9055G > A (p.A177T, MTATP6) mutation is the
defining variant for haplogroup K. It was predicted to be
damaging by the three algorithms, but was present both
in the patients and in the controls. It has been suspected
to be deleterious, as an excess of haplogroup K patients
has been found to convey a greater risk to lipodystrophy
among HIV-patients on antiretroviral therapy [57]. It is







ic 4 3 Finland, Japan
ic 6 3 Finland
0 2 Finland, China6
ic 4 3 USA, Native American, Kazakhstan
n.a. 0 n.a.
: Possibly damaging > 50%, probably damaging > 90%.
n levels: Damaging amino acid substitutions ≤ 0.05.
le).
u.se/ and among 8813 sequences in HmtDB database http://www.hmtdb.uniba.it
databases.
Soini et al. BMC Medical Genetics 2013, 14:73 Page 9 of 10
http://www.biomedcentral.com/1471-2350/14/73associated with haplogroup K. This haplogroup might
harbour several mtDNA variants that could impair mito-
chondrial function.
Conclusions
In this study, we found that the nonsynonymous mtDNA
variant m.15218A>G (p.T158A, MTCYB) is more common
in epilepsy patients with maternal family members with epi-
lepsy, SNHI or diabetes mellitus. The m.15218A>G variant
has previously been suggested to be mildly deleterious, which
was supported by our results. We suggest that mildly dele-
terious mtDNA mutations, such as m.15218A>G, may be
considered a risk factor for epilepsy in patients with maternal
relatives with SNHI, epilepsy or diabetes mellitus.
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